<DOC>
	<DOC>NCT00490828</DOC>
	<brief_summary>Hydrocortisone has been shown to improve the early outcome of high risk patients after cardiac surgery. A potential mechanism resulting in this effect may be its immunomodulatory action. In this prospective interventional study this hypothesis is to be proven.</brief_summary>
	<brief_title>Influence of Hydrocortisone on Immunologic Markers and Health Care Related Quality of Life in Patients After Cardiac Surgery</brief_title>
	<detailed_description>Methods: Prospective interventional randomized double blind placebo controlled study. Intervention: Hydrocortisone in stress doses vs. placebo Patients: 92 high risk patients after cardiac surgery Measurements: Cytokines, Toll-like receptors, NF kappa B, outcome data, health care related quality of life, PTSD.</detailed_description>
	<mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Preoperative left ventricular ejection fraction below 39 % duration of the extracorporeal circulation more than 97 min Pregnancy Severe liver insufficiency Severe renal insufficiency Insulin dependent diabetes mellitus Steroid therapy Psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Cardiac surgery</keyword>
	<keyword>systemic inflammatory response syndrome</keyword>
	<keyword>health-related quality of life</keyword>
</DOC>